Table S2.

Current treatment by CAT score domain in the USA

	Overall (N=413)	0–9 (n=60)	10–19 (n=116)	20–29 (n=172)	30–40 (n=65)
Current treatment, n (%)
Missing, n	3	1	1	1	0
Short-acting therapy
SABA, SAMA, SABA/SAMA alone	41 (10.0)	13 (22.0)	9 (7.8)	18 (10.5)	1 (1.5)
Maintenance therapies
Bronchodilator monotherapy
LAMA alone	73 (17.8)	14 (23.7)	29 (25.2)	24 (14.0)	6 (9.2)
LABA alone	5 (1.2)	0	1 (0.9)	4 (2.3)	0
Bronchodilator dual therapy
LABA+LAMA	5 (1.2)	1 (1.7)	1 (0.9)	2 (1.2)	1 (1.5)
Triple therapya
ICS/LABA+LAMA	132 (32.2)	13 (22.0)	37 (32.2)	60 (35.1)	22 (33.9)
LAMA+LABA+ICS	5 (1.2)	0	2 (1.7)	1 (0.6)	2 (3.1)
ICS-based therapies not including dual LA MA+LABA component
ICS alone	7 (1.7)	1 (1.7)	1 (0.9)	2 (1.2)	3 (4.6)
ICS/LABA alone	106 (25.9)	15 (25.4)	27 (23.5)	45 (26.3)	19 (29.2)
ICS+LAMA	10 (2.4)	1 (1.7)	3 (2.6)	4 (2.3)	2 (3.1)
ICS+LABA	6 (1.5)	0	0	4 (2.3)	2 (3.1)
ICS/LABA+LABA	0	0	0	0	0
ICS/LABA+LTRA	1 (0.2)	0	1 (0.9)	0	0
ICS/LABA+xanthines	0	0	0	0	0
ICS/LABA+ICS	0	0	0	0	0
ICS/LABA+ICS+LTRA	0	0	0	0	0
ICS/LABA+ICS+xanthines	1 (0.2)	0	1 (0.9)	0	0
ICS+xanthines	1 (0.2)	0	0	1 (0.6)	0
ICS+LTRA	1 (0.2)	0	0	1 (0.6)	0
Other maintenance therapy
LTRA alone	0	0	0	0	0
Xanthines alone	0	0	0	0	0
LABA+xanthines	0	0	0	0	0
ICS/LABA+LABA+LAMA	0	0	0	0	0
ICS/LABA+ICS+LAMA	1 (0.2)	0	0	0	1 (1.5)
Other	15 (3.7)	1 (1.7)	3 (2.6)	5 (2.9)	6 (9.2)

Note:

^aTriple therapy defined as a single LABA, a single LAMA and a single ICS therapy only.

Abbreviations: CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting β₂-agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist; SABA, short-acting β₂-agonist; SAMA, short-acting muscarinic antagonist.